Dynamics of Parameters of Transmitral Blood Flow and Markers of Myocardial Fibrosis in Patients with Myocardial Infarction

Aim      To study possible correlations between echocardiography (EchoCG) indexes and markers of myocardial fibrosis, procollagen I C-terminal propeptide (PICP) and procollagen III N-terminal propeptide (PIIINP) during one year following ST-segment elevation myocardial infarction (STEMI).

Material and methods  120 patients with STEMI were evaluated. EchoCG was used to assess dimensions and volumes of heart chambers, left ventricular (LV) systolic function, mean pulmonary arterial pressure (mPAP), and indexes of LV diastolic function (Em, early diastolic lateral mitral annular velocity; e’, peak early diastolic septal mitral annular velocity; E / e’, ratio of peak early diastolic transmitral inflow velocity and mitral annular velocity  –, Е / А, ratio of peak early and late transmitral inflow velocities; DT, deceleration time of LV early diastolic filling). EchoCG indexes and serum concentrations of PICP and PIIINP were determined at 1 (point 1) and 12 (point 2) days of disease and one year after STEMI (point 3). The sample was divided into two groups: group 1 (n=86; 71.7 %) included patients with a LV ejection fraction (EF) ≥50 % and group 2 (n=34; 28.3 %) consisted of patients with LV EF ≤49 %.

Results At one year, the number of patients with signs of diastolic dysfunction increased by 10% in group 1 whereas myocardial systolic dysfunction worsened in both groups. LV EF decreased in 15 (17.4%) patients of group 1 and in 4 (11.8%) patients of group 2. Concentrations of PIIINP were correlated with Em, E / e’, mPAP, PICP, e’, and LV EF.

Conclusion      Direct correlations between PIIINP concentrations and Em, E / e’, and mPAP were found in the group with LV EF ≥50 %. In the group with LV EF <50 %, correlations were observed between PICP concentrations, LV EF, and e’. Also, in this group, the increase in PIIINP was statistically more significant. These results indicate continuing formation of myocardial fibrosis in a year following MI, which may underlie progression of chronic heart failure.

1. Drapkina O.M., Gegenava B.B. Myocardial fibrosis in patients with diabetes mellitus. Rational Pharmacotherapy in Cardiology. 2013;9(1):62–5. DOI: 10.20996/1819-6446-2013-9-1-62-65

2. Muromtceva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T. M., Duplyakov D.V. et al. The prevalence of non-infectious disease risk factors in the Russian population in 2012-2013. Results of the ESSE-RF study. Cardiovascular Therapy and Prevention. 2014;13(6):4–11. DOI: 10.15829/1728-8800-2014-6-4-11

3. Drapkina O.M., Zyatenkova Е.V. Fibrosis markers in metabolic syndrome. Russian Medical Journal. 2016;24(26):1727–31.

4. Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Badin Yu.V., Galyavich A.S. et al. Prevalence of chronic heart failure in European part of Russian Federation - Data of AGE-CHF (Part II). Russian Heart Failure Journal. 2006;7(3):112–5.

5. Drapkina O.M., Zyatenkova Е.V. Assessment of the N-terminal collagen III- type propeptide in patients with chronic heart failure and metabolic syndrome. Cardiovascular Therapy and Prevention. 2015;14(6):42–7. DOI: 10.15829/1728-8800-2015-6-42-47

6. Karetnikova V.N., Kashtalap V.V., Kosareva S.N., Barbarash O.L. Myocardial fibrosis: Current aspects of the problem. Therapeutic Archive. 2017;89(1):88–93. DOI: 10.17116/terarkh201789188-93

7. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–164. DOI: 10.18087/cardio.2475

8. Pesheva O.V., Poltavskaya M.G., Giverts I.Yu., Dikur O.N., Sedov V.P., Syrkin A.L. Problems of diagnosis and epidemiology of chronic heart failure. Cardiology and cardiovascular surgery. 2014;7(4):75–83.

9. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29(4):277–314. DOI: 10.1016/j.echo.2016.01.011

10. Matyal R, Skubas NJ, Shernan SK, Mahmood F. Perioperative Assessment of Diastolic Dysfunction: Anesthesia & Analgesia. 2011;113(3):449–72. DOI: 10.1213/ANE.0b013e31822649ac

11. Titova A.L., Sayganov S.A. Diastolic function of the left ventricle in patients with coronary heart disease who underwent coronary artery bypass surgery. Russian family doctor. 2014;18(3):10–7.

12. Bartosh F.L., Bartosh L.F., Adonina T.S. Left ventricular diastolic function in hypertensive patients with atrial fibrillation. Arterial Hypertension. 2012;18(2):142–7. DOI: 10.18705/1607-419X-2012-18-2-142-147

13. Shilov S.N., Teplyakov A.T., Yakovleva I.V., Popova A.A., Berezikova E.N., Grakova E.V. et al. Clinical and pathogenic relationship between chronic heart failure, type 2 diabetes mellitus and osteoporosis. Complex Issues of Cardiovascular Diseases. 2018;7(1):6–13. DOI: 10.17802/2306-1278-2018-7-1-6-13

14. Weber KT, Sun Y, Campbell SE. Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. European Heart Journal. 1995;16(Suppl N):12–8. PMID: 8682056

15. Drapkina O.M., Gegenava B.B. Myocardial fibrosis in patients with diabetes mellitus. Rational Pharmacotherapy in Cardiology. 2013;9(1):62–5. DOI: 10.20996/1819-6446-2013-9-1-62-65

16. Drapkina O.M., Zyatenkova Е.V. Fibrosis markers in metabolic syndrome. Russian Medical Journal. 2016;24(26):1727–31.

17. Drapkina O.M., Zyatenkova Е.V. Assessment of the N-terminal collagen III- type propeptide in patients with chronic heart failure and metabolic syndrome. Cardiovascular Therapy and Prevention. 2015;14(6):42–7. DOI: 10.15829/1728-8800-2015-6-42-47